Use of 2-Methylene-19-Nor-(20S)-1alpha,25-Dihydroxyvitamin D3 to Treat Secondary Hyperparathyroidism
AssigneeWisconsin Alumni Research Foundation
InventorsHector F. DeLuca, Lori A. Plum, Julia B. Zella, Wendy Bedale, Margaret Clagett-Dame
Life of this patent
Estimating the term…
Abstract
Disclosed are methods of administering 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism.
Claims26
A method of preventing secondary hyperparathyroidism in a subject at risk of developing secondary hyperparathyroidism comprising administering a therapeutically effective amount of 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 or pharmaceutically acceptable salts thereof to the subject without inducing hypercalcemia in the subject wherein secondary hyperparathyroidism is prevented.
A method for treating secondary hyperparathyroidism or the symptoms thereof in a subject having secondary hyperparathyroidism comprising administering a therapeutically effective amount of 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 or pharmaceutically acceptable salts thereof to the subject without inducing hypercalcemia in the subject, wherein the secondary hyperparathyroidism or the symptoms thereof are treated.
A method of preventing symptoms of secondary hyperparathyroidism in a subject at risk of developing symptoms of secondary hyperparathyroidism comprising administering a therapeutically effective amount of 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 or pharmaceutically acceptable salts thereof to the subject without inducing hypercalcemia in the subject, wherein the symptoms of secondary hyperparathyroidism are prevented.
Dependencies are inferred from the claim text.